Intensity Modulated Radiation Therapy - Prostate Cancer

Inclusion Criteria: Histologic diagnosis of adenocarcinoma of the prostate within six months of entry Clinical stage T1B, T1C, T2A-C NX MO (see Appendix 1 for staging). Any Gleason score is eligible for entry, but Gleason score must be determined. Patients with a PSA >10.0 and Gleason score of 7; or patients with any PSA value and Gleason score of >8 must have clinically negative lymph nodes as determined by a pelvic CT scan done within 12 weeks of entry. A negative bone scan is required before entry for all patients with Gleason score >8, or any patient with a Gleason score of 7, and a PSA >10. The patient must not have received any cytotoxic anticancer therapy. Previous or concurrent hormonal therapy for local disease is acceptable. ECOG performance status of 1 or less Age 80 years old or less Serum PSA <25 ng/ml within 4 weeks of study entry Informed consent Exclusion Criteria: Patients with history of inflammatory bowel disease or other contraindication to radical radiation therapy Patients with prior colorectal surgery Any prior pelvic radiotherapy. Any prior TURP done <12 weeks from study entry. Any previous cytotoxic chemotherapy Patients with prior malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer